Abstract 297P
Background
Palliative care services are bieng provided to advanced cancer patients, and have traditionally included symptom directed therapy, counselling regarding goals of care and discussions centered around aggressiveness of care. An early palliative mliaison is bieng offered to patients with recently diagnosed tumours, but the ambit, purview and scope of these services has remained essentially unchanged.
Methods
Details of 127 patients admitted to the ward between over the course of three months were recorded and analysed.
Results
Analgesic titration (54 percent), interventional pain management (15 percent) and provision of supportive care services (23 percent) were the most common indications for admission. 44/123 patients (35.7 percent) received services which can be considered to be within the purview of supportive care. Bisphosphonate infusion for prevention of skeletal related events (12), pigtail catheter insertion for malignant pleural effusion (4), ultrasound guided therapeutic paracentesis (5), octreotide infusion for symptom control in neuroendocrine tumours and malignant bowel obstruction (3), management of difficult to control symptoms including dyspnoea and pain, malignant bowel obstruction (2), chemotherapy related complications (including febrile neutropenia, mucositis and diarrhea) were among services provided upon inpatient admission. 3 patients recieved chemotherapy. 13/127 recieved consultation liasion during their stay in the ward. Medical oncology liaison was the most commonly sought. The most commonly prescribed opioid was morphine followed by fentanyl and tramadol. Average duration of stay was 1.2 days with the longest admission lasting 5 days. The duration of stay was significantly longer for those who also recieved supportive care (p<0.01). Morphine equivalent daily dose, number of medications prescribed and Eastern cooperative oncology group performance status did not have any effect on the duration of stay.
Conclusions
The nature of services provided under the purview of this model, has the potential to ignite a larger debate on the impending and urgent need to redefine the scope of conventional Palliation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rahul D. Arora.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session